Kazuo Umezawa

Q: What Schools Are Affiliated With Kazuo Umezawa

Kazuo Umezawa is affiliated with the following schools: University of São Paulo, Osaka University, Kyoto University, Aichi Medical University, Hokkaido University, Brown University, Tokai University, University of Tokyo, Keio University, Kumamoto University

Kazuo Umezawa's AcademicInfluence.com Rankings

Kazuo Umezawa

Computer Science

#7992

World Rank

#8410

Historical Rank

Computational Linguistics

#1703

World Rank

#1721

Historical Rank

Machine Learning

#3146

World Rank

#3185

Historical Rank

Artificial Intelligence

#3447

World Rank

#3497

Historical Rank

computer-science Degrees

Download Badge

Computer Science

Kazuo Umezawa's Degrees

PhD Computer Science University of Tokyo
Masters Computer Science University of Tokyo
Bachelors Computer Science University of Tokyo

Similar Degrees You Can Earn

Why Is Kazuo Umezawa Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Kazuo Umezawa's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Requirement of Caspase-3(-like) Protease-mediated Hydrogen Peroxide Production for Apoptosis Induced by Various Anticancer Drugs* (1998) (292)
Inhibition of Tumor Necrosis Factor-α-induced Nuclear Translocation and Activation of NF-κB by Dehydroxymethylepoxyquinomicin* (2002) (192)
Suppression of diabetes-induced retinal inflammation by blocking the angiotensin II type 1 receptor or its downstream nuclear factor-kappaB pathway. (2007) (180)
Induction of nitric oxide synthesis and xanthine oxidase and their roles in the antimicrobial mechanism against Salmonella typhimurium infection in mice (1997) (161)
Synthesis of NF-κB activation inhibitors derived from epoxyquinomicin C (2000) (149)
Inhibition of RANKL‐Induced Osteoclastogenesis by (−)‐DHMEQ, a Novel NF‐κB Inhibitor, Through Downregulation of NFATc1 (2004) (147)
Production, isolation and structure determination of a novel beta-glucosidase inhibitor, cyclophellitol, from Phellinus sp. (1990) (133)
Selective inhibition of human neutrophil functional responsiveness by erbstatin, an inhibitor of tyrosine protein kinase. (1990) (129)
Dual targeting of transformed and untransformed HTLV-1-infected T cells by DHMEQ, a potent and selective inhibitor of NF-kappaB, as a strategy for chemoprevention and therapy of adult T-cell leukemia. (2005) (125)
Inhibition of epidermal growth factor‐induced DNA synthesis by tyrosine kinase inhibitors (1990) (123)
Similarity of teleocidin B and phorbol ester tumour promoters in effects on membrane receptors (1981) (123)
Macular Pigment Lutein Is Antiinflammatory in Preventing Choroidal Neovascularization (2007) (122)
Suppression of hormone-refractory prostate cancer by a novel nuclear factor kappaB inhibitor in nude mice. (2003) (122)
Induction of normal phenotypes in ras-transformed cells by damnacanthal from Morinda citrifolia. (1993) (120)
JunB induced by constitutive CD30-extracellular signal-regulated kinase 1/2 mitogen-activated protein kinase signaling activates the CD30 promoter in anaplastic large cell lymphoma and reed-sternberg cells of Hodgkin lymphoma. (2005) (119)
BRAFV600E promotes invasiveness of thyroid cancer cells through nuclear factor kappaB activation. (2006) (118)
Synthesis of N-substituted N-nitrosohydroxylamines as inhibitors of mushroom tyrosinase. (2001) (116)
Phenacyl photosensitive blocking groups (1973) (114)
Inactivation of NF-kappaB components by covalent binding of (-)-dehydroxymethylepoxyquinomicin to specific cysteine residues. (2008) (113)
TGF-β-induced epithelial-mesenchymal transition of A549 lung adenocarcinoma cells is enhanced by pro-inflammatory cytokines derived from RAW 264.7 macrophage cells. (2012) (113)
Targeting of nuclear factor kappaB Pathways by dehydroxymethylepoxyquinomicin, a novel inhibitor of breast carcinomas: antitumor and antiangiogenic potential in vivo. (2005) (111)
Hydrogen and N-acetyl-L-cysteine rescue oxidative stress-induced angiogenesis in a mouse corneal alkali-burn model. (2011) (108)
Genistein and daidzein induce cell proliferation and their metabolites cause oxidative DNA damage in relation to isoflavone-induced cancer of estrogen-sensitive organs. (2004) (107)
ErbB receptor tyrosine kinase/NF-κB signaling controls mammosphere formation in human breast cancer (2012) (105)
Identification of TIFA as an Adapter Protein That Links Tumor Necrosis Factor Receptor-associated Factor 6 (TRAF6) to Interleukin-1 (IL-1) Receptor-associated Kinase-1 (IRAK-1) in IL-1 Receptor Signaling* (2003) (99)
Gene set enrichment analysis provides insight into novel signalling pathways in breast cancer stem cells (2009) (96)
Inflammatory stimuli from macrophages and cancer cells synergistically promote tumor growth and angiogenesis (2007) (95)
Induction of Thyroid Cancer Cell Apoptosis by a Novel Nuclear Factor κB Inhibitor, Dehydroxymethylepoxyquinomicin (2004) (89)
Inhibition of tumor growth by NF‐κB inhibitors (2006) (87)
Neuronal Apoptosis by Apolipoprotein E4 through Low-Density Lipoprotein Receptor-Related Protein and Heterotrimeric GTPases (2000) (84)
Inhibition of Yin Yang 1-Dependent Repressor Activity of DR5 Transcription and Expression by the Novel Proteasome Inhibitor NPI-0052 Contributes to its TRAIL-Enhanced Apoptosis in Cancer Cells1 (2008) (83)
Rituximab inhibits the constitutively activated PI3K-Akt pathway in B-NHL cell lines: involvement in chemosensitization to drug-induced apoptosis (2007) (82)
Inhibition of tumor necrosis factor-alpha -induced nuclear translocation and activation of NF-kappa B by dehydroxymethylepoxyquinomicin. (2002) (73)
Molecular mechanisms regulating dissociation of cell–cell junction of epithelial cells by oxidative stress (2009) (72)
Effect of a small molecule inhibitor of nuclear factor-κB nuclear translocation in a murine model of arthritis and cultured human synovial cells (2005) (72)
Novel nuclear factor kappa B activation inhibitor prevents inflammatory injury in unilateral ureteral obstruction. (2003) (72)
Enhanced NF-κB Activity Impairs Vascular Function Through PARP-1–, SP-1–, and COX-2–Dependent Mechanisms in Type 2 Diabetes (2013) (69)
Molecular design and biological activities of NF-kappaB inhibitors. (2002) (67)
Cyclopentabenzofuran lignan protein synthesis inhibitors from Aglaia odorata. (1996) (65)
Chloptosin, an apoptosis-inducing dimeric cyclohexapeptide produced by Streptomyces. (2000) (64)
A novel NF‐κB inhibitor DHMEQ selectively targets constitutive NF‐κB activity and induces apoptosis of multiple myeloma cells in vitro and in vivo (2005) (63)
Synthesis of NF-kappaB activation inhibitors derived from epoxyquinomicin C. (2000) (63)
Novel benzylidene-9(10H)-anthracenones as highly active antimicrotubule agents. Synthesis, antiproliferative activity, and inhibition of tubulin polymerization. (2003) (61)
Inhibition of abl Oncogene Tyrosine Kinase Induces Erythroid Differentiation of Human Myelogenous Leukemia K562 Cells (1990) (61)
Polyoxypeptins A and B Produced by Streptomyces: Apoptosis-Inducing Cyclic Depsipeptides Containing the Novel Amino Acid (2S,3R)-3-Hydroxy-3-methylproline. (1999) (61)
Induction by the guanosine analogue oxanosine of reversion toward the normal phenotype of K-ras-transformed rat kidney cells. (1989) (61)
Naturally occurring and synthetic inhibitors of NF-kappaB functions. (2000) (61)
The first direct synthesis of α-mangostin, a potent inhibitor of the acidic sphingomyelinase (2002) (60)
Involvement of hydrogen peroxide production in erbstatin-induced apoptosis in human small cell lung carcinoma cells. (1996) (60)
Kinetic studies of tyrosine kinase inhibition by erbstatin. (1987) (58)
Biological activities of cyclophellitol. (1990) (58)
In vivo antitumor activity of the NF-kappaB inhibitor dehydroxymethylepoxyquinomicin in a mouse model of adult T-cell leukemia. (2005) (57)
Protein tyrosine kinase inhibitors inhibit chemotaxis of vascular smooth muscle cells. (1994) (56)
Mutagenicity of aclacinomycin A and daunomycin derivatives. (1978) (56)
Promotion of beta-cell differentiation by conophylline in fetal and neonatal rat pancreas. (2004) (55)
Effects of inhibitors of protein tyrosine kinase activity and/or phosphatidylinositol turnover on differentiation of some human myelomonocytic leukemia cells. (1991) (55)
Inhibition of macrophage activation and phagocytosis by a novel NF-kappaB inhibitor, dehydroxymethylepoxyquinomicin. (2006) (55)
Preparation and biological activities of optically active dehydroxymethylepoxyquinomicin, a novel NF-κB inhibitor (2004) (55)
Comutagenic effect of norharman and harman with 2-acetylaminofluorene derivatives. (1978) (55)
Enantiospecific Total Synthesis of a β-Glucosidase Inhibitor, Cyclophellitol (1990) (54)
Galectin-3 Up-Regulation in Hypoxic and Nutrient Deprived Microenvironments Promotes Cell Survival (2014) (54)
Molecular design and biological activities of protein-tyrosine phosphatase inhibitors. (2003) (54)
Isolation of a new vinca alkaloid from the leaves of Ervatamia microphylla as an inhibitor of ras functions. (1994) (51)
Inhibition of Experimental Metastasis by an α-Glucosidase Inhibitor, 1,6-Epi-cyclophellitol (1993) (51)
Stimulation of ultraviolet‐induced apoptosis of human fibroblast UVr‐1 cells by tyrosine kinase inhibitors (1999) (51)
Chemosensitization and immunosensitization of resistant cancer cells to apoptosis and inhibition of metastasis by the specific NF-kappaB inhibitor DHMEQ. (2009) (50)
Cyclophellitol: a naturally occurring mechanism-based inactivator of beta-glucosidases. (1991) (50)
DHMEQ, a new NF-κB inhibitor, induces apoptosis and enhances fludarabine effects on chronic lymphocytic leukemia cells (2006) (50)
Tyrosine Kinase Inhibitors Inhibit Multiple Steps of the Cell Cycle of Vascular Smooth Muscle Cells (1995) (49)
Conophylline suppresses pancreatic stellate cells and improves islet fibrosis in Goto-Kakizaki rats. (2012) (48)
Possible role of peritoneal NF-κB in peripheral inflammation and cancer: lessons from the inhibitor DHMEQ. (2011) (48)
Antitumor Effects of Dehydroxymethylepoxyquinomicin, a Novel Nuclear Factor-κB Inhibitor, in Human Liver Cancer Cells Are Mediated through a Reactive Oxygen Species-Dependent Mechanism (2009) (48)
A simple method to induce differentiation of murine bone marrow mesenchymal cells to insulin-producing cells using conophylline and betacellulin-delta4. (2008) (48)
Inhibition of cellular phosphatidylinosito, turnover by psi‐tectorigenin (1988) (47)
Granulocyte-macrophage colony-stimulating factor primes phospholipase D activity in human neutrophils in vitro: role of calcium, G-proteins and tyrosine kinases. (1992) (46)
A novel NF-κB inhibitor, dehydroxymethylepoxyquinomicin, ameliorates inflammatory colonic injury in mice. (2012) (46)
Nitric Oxide Donors Induce Neurotrophin-Like Survival Signaling and Protect Neurons against Apoptosis (2005) (45)
Induction of sister chromatid exchanges by nicotinamide in Chinese hamster lung fibroblasts and human lymphoblastoid cells. (1979) (45)
Advances in Targeting Signal Transduction Pathways (2012) (45)
Induction of hydrogen peroxide production and Bax expression by caspase-3(-like) proteases in tyrosine kinase inhibitor-induced apoptosis in human small cell lung carcinoma cells. (1998) (44)
Nitric oxide mediates murine cytomegalovirus-associated pneumonitis in lungs that are free of the virus. (1997) (44)
Antitumor activity of erbstatin, a tyrosine protein kinase inhibitor. (1987) (44)
Polyoxypeptin isolated from Streptomyces: A bioactive cyclic depsipeptide containing the novel amino acid 3-hydroxy-3-methylproline (1998) (44)
Pentalenene Synthase. Histidine-309 Is Not Required for Catalytic Activity (1999) (43)
The novel NF-kappaB inhibitor, dehydroxymethylepoxyquinomicin, prevents local and remote organ injury following intestinal ischemia/reperfusion in rats. (2008) (43)
Determination of cathepsin V activity and intracellular trafficking by N‐glycosylation (2012) (43)
Isolation and structure determination of inostamycin, a novel inhibitor of phosphatidylinositol turnover (1990) (43)
Isolation of a novel cyclic hexadepsipeptide pipalamycin from Streptomyces as an apoptosis-inducing agent. (2002) (42)
Conophylline Protects Cells in Cellular Models of Neurodegenerative Diseases by Inducing Mammalian Target of Rapamycin (mTOR)-independent Autophagy* (2015) (42)
A Selective NFκB Inhibitor, DHMEQ, Reduced Atherosclerosis in ApoE-deficient mice (2006) (42)
Induction of insulin production in rat pancreatic acinar carcinoma cells by conophylline. (2003) (42)
Glyoxalase-I is a novel target against Bcr-Abl+ leukemic cells acquiring stem-like characteristics in a hypoxic environment (2010) (41)
Aberrant Expression of NF-κB in Liver Fluke Associated Cholangiocarcinoma: Implications for Targeted Therapy (2014) (41)
Inhibition of tyrosine protein kinase by synthetic erbstatin analogs. (1987) (41)
DHMEQ, a novel NF-kappaB inhibitor, induces apoptosis and cell-cycle arrest in human hepatoma cells. (2006) (40)
A new bioactive steroidal saponin, furcreastatin, from the plant Furcraea foetida. (1999) (40)
Antitumor effect of a novel nuclear factor-κB activation inhibitor in bladder cancer cells (2003) (40)
Inhibition of Lipopolysaccharide Activity by a Bacterial Cyclic Lipopeptide Surfactin (2006) (40)
Prevention of Cancer Cachexia by a Novel Nuclear Factor κB Inhibitor in Prostate Cancer (2005) (39)
Suppression of cellular invasion by glybenclamide through inhibited secretion of platelet‐derived growth factor in ovarian clear cell carcinoma ES‐2 cells (2012) (39)
Antidiabetic effect of orally administered conophylline-containing plant extract on streptozotocin-treated and Goto-Kakizaki rats. (2009) (38)
Synthesis and tyrosinase inhibitory activity of novel N-hydroxybenzyl-N-nitrosohydroxylamines. (2003) (38)
Inhibition of tumor growth by NF-kappaB inhibitors. (2006) (38)
C-mannosylation of human hyaluronidase 1: possible roles for secretion and enzymatic activity. (2014) (37)
The Neuroprotective Effect of Rapamycin as a Modulator of the mTOR-NF-κB Axis during Retinal Inflammation (2016) (37)
Use of erbstatin as protein-tyrosine kinase inhibitor. (1991) (37)
In vitro and in vivo antitumor activity of the NF-kappaB inhibitor DHMEQ in the human T-cell leukemia virus type I-infected cell line, HUT-102. (2006) (36)
A small molecule inhibitor of NF-kappaB, dehydroxymethylepoxyquinomicin (DHMEQ), suppresses growth and invasion of nasopharyngeal carcinoma (NPC) cells. (2010) (36)
Antineoplastic effect of erbstatin on human mammary and esophageal tumors in athymic nude mice. (1990) (36)
Dehydroxymethylepoxyquinomicin, a novel nuclear Factor-kappaB inhibitor, enhances antitumor activity of taxanes in anaplastic thyroid cancer cells. (2008) (36)
Biscoclaurine alkaloid cepharanthine inhibits the growth of primary effusion lymphoma in vitro and in vivo and induces apoptosis via suppression of the NF‐κB pathway (2009) (36)
Design, synthesis, and biological evaluation of novel estradiol-bisphosphonate conjugates as bone-specific estrogens. (2010) (36)
Involvement of autocrine CXCL12/CXCR4 system in the regulation of ovarian carcinoma cell invasion. (2010) (36)
Potentiation of Insulin-related Signal Transduction by a Novel Protein-tyrosine Phosphatase Inhibitor, Et-3,4-dephostatin, on Cultured 3T3-L1 Adipocytes* (2001) (35)
Inhibition of Acidic Sphingomyelinase by Xanthone Compounds Isolated from Garcinia Speciosa (2000) (35)
Induction of G1 arrest and selective growth inhibition by lactacystin in human umbilical vein endothelial cells. (1999) (35)
Role of NF‐κB/Snail/RKIP loop in the response of tumor cells to photodynamic therapy (2011) (34)
Identification of the RelA domain responsible for action of a new NF-kappaB inhibitor DHMEQ. (2008) (34)
A novel NF-kappaB inhibitor DHMEQ selectively targets constitutive NF-kappaB activity and induces apoptosis of multiple myeloma cells in vitro and in vivo. (2005) (34)
Conophylline: a novel differentiation inducer for pancreatic beta cells. (2006) (34)
Syntheses and enzyme inhibiting activities of cyclophellitol analogs. (1991) (34)
Down-regulation of NF kappa B activation is an effective therapeutic modality in acquired platinum-resistant bladder cancer (2015) (33)
Reversal of resistance to cytotoxic cancer therapies: DHMEQ as a chemo-sensitizing and immuno-sensitizing agent. (2007) (33)
Control of Allograft Rejection by Applying a Novel Nuclear Factor-&kgr;B Inhibitor, Dehydroxymethylepoxyquinomicin (2006) (32)
Antitumor effect of dehydroxymethylepoxyquinomicin, a small molecule inhibitor of nuclear factor-κB, on glioblastoma. (2012) (32)
Inhibition of NF-κB by Dehydroxymethylepoxyquinomicin Suppresses Invasion and Synergistically Potentiates Temozolomide and γ-Radiation Cytotoxicity in Glioblastoma Cells (2013) (32)
Enantiospecific synthesis and biological evaluation of 1,6-epi-cyclophellitol. (1991) (32)
Induction of Indoleamine 2, 3-Dioxygenase in Human Dendritic Cells by a Cholera Toxin B Subunit—Proinsulin Vaccine (2015) (32)
Inhibition of phosphatidylinositol kinase by toyocamycin. (1990) (32)
Total syntheses of glucosidase inhibitors, cyclophellitols (1991) (32)
Novel approaches to target NF-κB and other signaling pathways in cancer stem cells. (2014) (32)
Inhibition of macrophage activation and suppression of graft rejection by DTCM-glutarimide, a novel piperidine derived from the antibiotic 9-methylstreptimidone (2011) (31)
Dehydroxymethylepoxyquinomicin (DHMEQ), a novel NF‐kappaB inhibitor, inhibits allergic inflammation and airway remodelling in murine models of asthma (2012) (31)
The novel NF-κB inhibitor DHMEQ synergizes with celecoxib to exert antitumor effects on human liver cancer cells by a ROS-dependent mechanism. (2012) (30)
Impairment of Plasmacytoid Dendritic Cells for IFN Production by the Ligand for Immunoglobulin-Like Transcript 7 Expressed on Human Cancer Cells (2009) (30)
Survivin associates with cell proliferation in renal cancer cells: Regulation of survivin expression by insulin-like growth factor-1, interferon-γ and a novel NF-κB inhibitor (2006) (29)
Inhibition of DNA topoisomerases I and II and induction of apoptosis by erbstatin and tyrphostin derivatives. (1994) (29)
Isolation of a New Indole Alkaloid, Pendolmycin, from Nocardiopsis (1988) (29)
Enhanced susceptibility to lipopolysaccharide-induced arthritis and endotoxin shock in interleukin-32 alpha transgenic mice through induction of tumor necrosis factor alpha (2012) (29)
Dehydroxymethylepoxyquinomicin, a novel nuclear factor-κB inhibitor, induces apoptosis in multiple myeloma cells in an IκBα-independent manner (2005) (29)
Characterizing the involvement of the nuclear factor-kappa B (NF kappa B) transcription factor in uveal melanoma. (2010) (28)
Inhibition of experimental blood-borne lung metastasis by protease inhibitors. (1980) (28)
Dehydroxymethylepoxyquinomicin (DHMEQ) therapy reduces tumor formation in mice inoculated with tax-deficient adult T-cell leukemia-derived cell lines. (2007) (28)
Akaterpin, a Novel Bioactive Triterpene from the Marine Sponge Callyspongia sp. (1997) (28)
Biosynthesis of polyoxypeptin A: novel amino acid 3-hydroxy-3-methylproline derived from isoleucine (2001) (27)
Enhancement or induction of neurite formation by a protein tyrosine phosphatase inhibitor, 3,4-dephostatin, in growth factor-treated PC12h cells. (1997) (27)
DHMEQ, a novel NF-kappaB inhibitor, suppresses growth and type I collagen accumulation in keloid fibroblasts. (2008) (27)
Combined effect of dehydroxymethylepoxyquinomicin and gemcitabine in a mouse model of liver metastasis of pancreatic cancer (2013) (27)
NF-κB inhibitor dehydroxymethylepoxyquinomicin suppresses osteoclastogenesis and expression of NFATc1 in mouse arthritis without affecting expression of RANKL, osteoprotegerin or macrophage colony-stimulating factor (2007) (26)
Structure–Activity Relationship and Rational Design of 3,4-Dephostatin Derivatives as Protein Tyrosine Phosphatase Inhibitors (2000) (26)
Polymorphonuclear cells in chronic hemodialysis patients have intact phagocytotic and impaired bactericidal activities. (1997) (26)
Activation of the respiratory burst and tyrosine phosphorylation of proteins in human neutrophils: no direct relationship and involvement of protein kinase C-dependent and -independent signaling pathways. (1993) (26)
A Novel Nuclear Factor κB Inhibitor, Dehydroxymethylepoxyquinomicin, Ameliorates Puromycin Aminonucleoside-Induced Nephrosis in Mice (2013) (25)
Inhibition of CDP-DG: inositol transferase by inostamycin. (1992) (25)
The role of inflammatory chemokines in lymphoid neoorganogenesis in breast cancer. (2013) (25)
The NF-κB inhibitors (bortezomib and DHMEQ) sensitise rituximab-resistant AIDS-B-non-Hodgkin lymphoma to apoptosis by various chemotherapeutic drugs (2008) (25)
Reversal of anticancer drug resistance by COTC based on intracellular glutathione and glyoxalase I. (2005) (25)
Pholipeptin, a Novel Cyclic Lipoundecapeptide fromPseudomonas fluorescens. (1997) (25)
Accumulation of tissue glucosylsphingosine in Gaucher-like mouse induced by the glucosylceramidase inhibitor cyclophellitol. (1993) (25)
Strategic targeting of the PI3K–NFκB axis in cisplatin-resistant NSCLC (2014) (25)
Effects of a novel NF‐κB inhibitor, dehydroxymethylepoxyquinomicin (DHMEQ), on growth, apoptosis, gene expression, and chemosensitivity in head and neck squamous cell carcinoma cell lines (2006) (25)
Inhibition of MMP-2-mediated cellular invasion by NF-κB inhibitor DHMEQ in 3D culture of breast carcinoma MDA-MB-231 cells: A model for early phase of metastasis. (2017) (24)
AMPK-NF-κB Axis in the Photoreceptor Disorder during Retinal Inflammation (2014) (24)
Inhibition of glucocerebrosidase and induction of neural abnormality by cyclophellitol in mice. (1992) (24)
Involvement of DNA binding domain in the cellular stability and importin affinity of NF-κB component RelB. (2012) (24)
Cellular uptake and efflux and cytostatic activity of 4'-O-tetrahydropyranyladriamycin in adriamycin-sensitive and resistant tumor cell lines. (1984) (24)
Biological activities of α-mangostin derivatives against acidic sphingomyelinase (2003) (24)
Inhibition of Late and Early Phases of Cancer Metastasis by the NF-κB Inhibitor DHMEQ Derived from Microbial Bioactive Metabolite Epoxyquinomicin: A Review (2018) (24)
Isolation of a novel substrate‐competitive tyrosine kinase inhibitor, desmal, from the plant Desmos chinensis (1993) (23)
Synthesis and biological evaluation on novel analogs of 9-methylstreptimidone, an inhibitor of NF-kappaB. (2009) (23)
Inhibition of Cyclin D1 Expression and Induction of Apoptosis by Inostamycin in Small Cell Lung Carcinoma Cells (1998) (23)
Caspase‐3 Activation Is Not Responsible for Vinblastine‐induced Bcl‐2 Phosphorylation and G2/M Arrest in Human Small Cell Lung Carcinoma Ms‐1 Cells (1998) (23)
A novel inhibitor of farnesyltransferase with a zinc site recognition moiety and a farnesyl group. (2017) (23)
Inhibition of tumor angiogenesis by targeting endothelial surface ATP synthase with sangivamycin. (2007) (22)
p62/SQSTM1 plays a protective role in oxidative injury of steatotic liver in a mouse hepatectomy model. (2014) (22)
Granulation in livers of mice infected with Salmonella typhimurium is caused by superoxide released from host phagocytes (1995) (22)
Amelioration of experimental autoimmune uveoretinitis with nuclear factor-{kappa}B Inhibitor dehydroxy methyl epoxyquinomicin in mice. (2010) (22)
Inhibition of G1 cyclin expression in normal rat kidney cells by inostamycin, a phosphatidylinositol synthesis inhibitor. (1996) (22)
Conophylline suppresses pancreatic cancer desmoplasia and cancer‐promoting cytokines produced by cancer‐associated fibroblasts (2018) (22)
Angiopoietin-like Protein 2 Is a Multistep Regulator of Inflammatory Neovascularization in a Murine Model of Age-related Macular Degeneration* (2016) (21)
Placenta growth factor induces melanoma resistance to temozolomide through a mechanism that involves the activation of the transcription factor NF-κB. (2010) (21)
Efficacy of DHMEQ, a NF-&kgr;B Inhibitor, in Islet Transplantation: I. HMGB1 Suppression by DHMEQ Prevents Early Islet Graft Damage (2013) (21)
Growth inhibition of K-ras-expressing tumours by a new vinca alkaloid, conophylline, in nude mice. (1996) (21)
Suppression of in vitro invasion of human fibrosarcoma cells by a leupeptin analogue inhibiting the urokinase-plasmin system. (1995) (21)
The unfolded protein response mediated by PERK is casually related to the pathogenesis of intervertebral disc degeneration (2018) (21)
Morphological transformation, sister chromatid exchange and mutagenesis assay of betel constituents. (1981) (21)
Inhibition of nuclear factor-&kgr;B by dehydroxymethylepoxyquinomicin induces schedule-dependent chemosensitivity to anticancer drugs and enhances chemoinduced apoptosis in osteosarcoma cells (2012) (21)
Inhibition of tumor cell invasion in the Boyden chamber assay by a mannosidase inhibitor, mannostatin A. (1993) (21)
Transient inhibition of NF‐κB by DHMEQ induces cell death of primary effusion lymphoma without HHV‐8 reactivation (2009) (21)
The NF-κB specific inhibitor DHMEQ prevents thrombus formation in a mouse model of antiphospholipid syndrome. (2013) (21)
Blocking NF-kappaB as a potential strategy to treat adult T-cell leukemia/lymphoma. (2006) (21)
The differential statin effect on cytokine production of monocytes or macrophages is mediated by differential geranylgeranylation-dependent Rac1 activation (2019) (21)
Involvement of NF-κB-mediated expression of galectin-3-binding protein in TNF-α-induced breast cancer cell adhesion. (2012) (20)
Antitumor effect of piericidin B1 N-oxide. (1994) (20)
JAK/STAT3 and NF-κB Signaling Pathways Regulate Cancer Stem-Cell Properties in Anaplastic Thyroid Cancer Cells. (2019) (20)
Enhancement of the caspase-independent apoptotic sensitivity of pancreatic cancer cells by DHMEQ, an NF-kappaB inhibitor. (2005) (20)
Conophylline suppresses hepatic stellate cells and attenuates thioacetamide‐induced liver fibrosis in rats (2014) (20)
The Novel NF-κB Activation Inhibitor Dehydroxymethyl-Epoxyquinomicin Suppresses Anti-Thy1.1-Induced Glomerulonephritis in Rats (2008) (20)
Staphylococcal delta-hemolysin inhibits cellular binding of epidermal growth factor and induces arachidonic acid release. (1980) (20)
Prevention of cancer cachexia by a novel nuclear factor {kappa}B inhibitor in prostate cancer. (2005) (20)
Involvement of phosphatidylinositol synthesis in the regulation of S phase induction. (1994) (20)
The side population, as a precursor of Hodgkin and Reed‐Sternberg cells and a target for nuclear factor‐κB inhibitors in Hodgkin’s lymphoma (2010) (19)
Efficient synthesis of (+/-)-parasitenone, a novel inhibitor of NF-kappaB. (2009) (19)
Donor pretreatment with DHMEQ improves islet transplantation. (2010) (19)
Induction of apoptosis in Epstein-Barr virus-infected B-lymphocytes by the NF-kappaB inhibitor DHMEQ. (2008) (19)
Inhibition of nuclear factor‐kappaB suppresses peritoneal dissemination of gastric cancer by blocking cancer cell adhesion (2011) (19)
Coffee induces breast cancer resistance protein expression in Caco-2 cells. (2011) (19)
Inhibition of NF-κB Activity Enhances Sensitivity to Anticancer Drugs in Cholangiocarcinoma Cells. (2016) (19)
Molecular design, chemical synthesis and biological evaluation of quinoxaline-carbohydrate hybrids as novel and selective photo-induced DNA cleaving and cytotoxic agents (2003) (19)
Activation and cleavage of SASH1 by caspase-3 mediates an apoptotic response (2016) (18)
Efficient cellular uptake of the novel NF-kappaB inhibitor (-)-DHMEQ and irreversible inhibition of NF-kappaB in neoplastic cells. (2009) (18)
Screening for inducers of apoptosis in apoptosis-resistant human carcinoma cells. (1999) (18)
Antimutagenic Effect of Elastatinal, a Protease Inhibitor from Actinomycetes (1977) (18)
Promotion of beta-cell differentiation by the alkaloid conophylline in porcine pancreatic endocrine cells. (2010) (18)
Conophylline inhibits high fat diet-induced non-alcoholic fatty liver disease in mice (2019) (18)
A selective NFkappaB inhibitor, DHMEQ, reduced atherosclerosis in ApoE-deficient mice. (2006) (18)
Isolation of heptadepsin, a novel bacterial cyclic depsipeptide that inhibits lipopolysaccharide activity. (2004) (17)
Microenvironmental stromal cells abrogate NF-κB inhibitor-induced apoptosis in chronic lymphocytic leukemia (2017) (17)
Teleocidin: new naturally occurring tumor promoter. (1982) (17)
Conophylline inhibits non-alcoholic steatohepatitis in mice (2017) (17)
Amelioration of Severe TNBS Induced Colitis by Novel AP-1 and NF-κB Inhibitors in Rats (2014) (17)
Efficacy of DHMEQ, a NF-&kgr;B Inhibitor, in Islet Transplantation: II. Induction DHMEQ Treatment Ameliorates Subsequent Alloimmune Responses and Permits Long-Term Islet Allograft Acceptance (2013) (17)
Therapeutic activity of plant-derived alkaloid conophylline on metabolic syndrome and neurodegenerative disease models (2018) (17)
Inhibition of NF-kappaB and Akt pathways by an antibody-avidin fusion protein sensitizes malignant B-cells to cisplatin-induced apoptosis. (2010) (17)
Inhibition of cellular chemotactic invasion by a vinca alkaloid, conophylline. (1996) (17)
Inhibition of NF-κB Activity Enhances Sensitivity to Anticancer Drugs in Cholangiocarcinoma Cells (2016) (17)
Preferential inhibition of glioblastoma cells with wild-type epidermal growth factor receptors by a novel tyrosine kinase inhibitor ethyl-2,5-dihydroxycinnamate. (1997) (16)
DSE-FRET: A new anticancer drug screening assay for DNA binding proteins (2014) (16)
A novel metal-chelating inhibitor of protein farnesyltransferase. (2003) (16)
Inhibition of inflammatory mediator secretion by (-)-DHMEQ in mouse bone marrow-derived macrophages. (2009) (16)
IκBα independent induction of NF-κB and its inhibition by DHMEQ in Hodgkin/Reed-Sternberg cells (2007) (16)
Inhibition of phosphatidylinositol-specific phospholipase C activity by fluvirucin B2. (1995) (16)
Survivin associates with cell proliferation in renal cancer cells: regulation of survivin expression by insulin-like growth factor-1, interferon-gamma and a novel NF-kappaB inhibitor. (2006) (16)
Neuronal cell apoptosis by a receptor-binding domain peptide of ApoE4, not through low-density lipoprotein receptor-related protein. (2000) (16)
Induction of cellular differentiation and apoptosis by signal transduction inhibitors. (1997) (16)
The NF-κB inhibitor DHMEQ decreases survival factors, overcomes the protective activity of microenvironment and synergizes with chemotherapy agents in classical Hodgkin lymphoma. (2014) (16)
Thrombomodulin blocks calcineurin inhibitor-induced vascular permeability via inhibition of Src/VE-cadherin axis (2017) (16)
Novel metal chelating molecules with anticancer activity. Striking effect of the imidazole substitution of the histidine-pyridine-histidine system. (2015) (15)
Isolation from Streptomyces of a novel naphthoquinone compound, naphthablin, that inhibits Abl oncogene functions. (1995) (15)
Preparation and Biological Activities of Optically Active Dehydroxymethylepoxyquinomicin, a Novel NF-ϰB Inhibitor. (2004) (15)
Isolation and biological activities of signal transduction inhibitors from microorganisms and plants. (1995) (15)
Inhibition of Abelson oncogene function by erbstatin analogues. (1993) (15)
Possible Involvement of Chemokine‐induced Platelet Activation in Thrombophilic Diathesis of Antiphospholipid Syndrome (2009) (15)
Topical application of dehydroxymethylepoxyquinomicin improves allergic inflammation via NF-kappaB inhibition. (2010) (15)
Potentiation of Paclitaxel Cytotoxicity by Inostamycin in Human Small Cell Lung Carcinoma, Ms‐1 Cells (1998) (15)
Effect of a Novel Nuclear Factor-&kgr;B Activation Inhibitor on Renal Ischemia-Reperfusion Injury (2013) (15)
Inhibition by two lavendustins of the tyrosine kinase activity of pp60F527 in vitro and in intact cells. (1994) (15)
Determination of topological structure of ARL6ip1 in cells: Identification of the essential binding region of ARL6ip1 for conophylline (2013) (15)
In situ inhibition of tyrosine protein kinase by erbstatin. (1987) (14)
Earthworm-Derived Pore-Forming Toxin Lysenin and Screening of Its Inhibitors (2013) (14)
Unusual intramolecular N-->O acyl group migration occurring during conjugation of (-)-DHMEQ with cysteine. (2009) (14)
Inhibition of inflammatory cytokine secretion from mouse microglia cells by DHMEQ, an NF-kappaB inhibitor. (2005) (14)
Long‐lasting Accumulation of Vinblastine in Inostamycin‐treated Multidrug‐resistant KB Cells (1991) (14)
Pendolmycin, a New Tumor Promoter of the Teleocidin A Class on Skin of CD‐1 Mice (1991) (14)
External application of NF-κB inhibitor DHMEQ suppresses development of atopic dermatitis-like lesions induced with DNCB/OX in BALB/c mice (2017) (14)
Novel approaches to target cancer initiating cells-eliminating the root of the cancer. (2012) (14)
Overexpression of Phosphatidylinositol Synthase Enhances Growth and G1 Progression in NIH3T3 cells (2002) (13)
Inhibition of MMP-2-Mediated Mast Cell Invasion by NF-κB Inhibitor DHMEQ in Mast Cells (2015) (13)
Inhibition of cellular inflammatory mediator production and amelioration of learning deficit in flies by deep sea Aspergillus-derived cyclopenin (2020) (13)
Inhibition of attachment and chemotactic invasion of uterine endometrial cancer cells by a new vinca alkaloid, conophylline. (1999) (13)
Dehydroxymethylepoxyquinomicin, a novel nuclear factor-kappaB inhibitor, induces apoptosis in multiple myeloma cells in an IkappaBalpha-independent manner. (2005) (13)
Potent cytotoxic effect of a novel nuclear factor-kappaB inhibitor dehydroxymethylepoxyquinomicin on human bladder cancer cells producing various cytokines. (2010) (13)
Inhibition of matrix metalloproteinase expression and cellular invasion by NF-κB inhibitors of microbial origin. (2020) (13)
DHMEQ, a novel nuclear factor‐κB inhibitor, induces selective depletion of alloreactive or phytohaemagglutinin‐stimulated peripheral blood mononuclear cells, decreases production of T helper type 1 cytokines, and blocks maturation of dendritic cells (2008) (13)
Tetrahydrobiopterin Biosynthesis Enhanced by Lipopolysaccharide Stimulation in Murine Neuroblastoma Cell Line N1E‐115 (1996) (13)
Regulation of human dendritic cells by a novel specific nuclear factor-kappaB inhibitor, dehydroxymethylepoxyquinomicin. (2010) (13)
Induction of c-fos and c-myc oncogene expression in the pyloric mucosa of rat stomach by N-methyl-N'-nitro-N-nitrosoguanidine and taurocholate. (1994) (12)
Inhibition of experimental metastasis by an alpha-glucosidase inhibitor, 1,6-epi-cyclophellitol. (1993) (12)
Migracins A and B, new inhibitors of cancer cell migration, produced by Streptomyces sp. (2012) (12)
Dual Agonist of Farnesoid X Receptor and Takeda G Protein‐Coupled Receptor 5 Inhibits Hepatitis B Virus Infection In Vitro and In Vivo (2021) (12)
Chemoenzymatic synthesis of (2R,3R,4R)-dehydroxymethylepoxyquinomicin (DHMEQ), a new activator of antioxidant transcription factor Nrf2. (2011) (12)
Inhibition of chemically induced sister chromatid exchanges by elastatinal. (1979) (12)
Synthesis of sugar-modified derivatives of the unusual nucleoside oxanosine and its carbocyclic analogs as potential inhibitors of HIV (2001) (12)
Chemoenzymatic synthesis of (2S,3S,4S)-form, the physiologically active stereoisomer of dehydroxymethylepoxyquinomicin (DHMEQ), a potent inhibitor on NF-κB (2010) (12)
Pleiotropic Potential of Dehydroxymethylepoxyquinomicin for NF-κB Suppression via Reactive Oxygen Species and Unfolded Protein Response (2013) (12)
Synthesis and Structure–Activity Relationship of Dehydroxymethylepoxyquinomicin Analogues as Inhibitors of NF-κB Functions (2002) (12)
Inhibition of Canonical NF-κB Nuclear Localization by (−)-DHMEQ via Impairment of DNA Binding (2015) (12)
Total synthesis of (±)-aglaiastatin, a novel bioactive alkaloid (1998) (12)
Suppression of Inflammatory Cytokine Secretion by an NF-ĸB Inhibitor DHMEQ in Nasal Polyps Fibroblasts (2012) (12)
Administration of conophylline and betacellulin-δ4 increases the β-cell mass in neonatal streptozotocin-treated rats (2009) (11)
Enhancement of the mutagenicities of N-methyl-N'-nitro-N-nitrosoguanidine and N-methyl-N-nitrosourea by glucose. (1980) (11)
Conophylline and Betacellulin-δ4 : an Effective Combination of Differentiation Factors for Pancreatic β Cells (2007) (11)
Inhibition of EGF-induced phospholipase C activation in A431 cells by erbstatin, a tyrosine kinase inhibitor. (1990) (11)
Inhibition of nuclear factor-κB signaling suppresses Spint1-deletion-induced tumor susceptibility in the ApcMin/+ model (2016) (11)
Suppression of TGF-β signaling by conophylline via upregulation of c-Jun expression (2003) (11)
Isolation of a novel paxilline analog pyrapaxilline from fungus that inhibits LPS-induced NO production (2014) (11)
Growth suppression and apoptosis induction in synovial sarcoma cell lines by a novel NF-kappaB inhibitor, dehydroxymethylepoxyquinomicin (DHMEQ). (2008) (11)
Rituximab inhibits the constitutively activated PI3K-Akt pathway in B-NHL cell lines: involvement in chemosensitization to drug-induced apoptosis (2007) (11)
Targeting NF-κB and induction of apoptosis by novel NF-κB inhibitor dehydroxymethylepoxyquinomicin (DHMEQ) in Burkitt lymphoma cells (2007) (11)
In vitro transformation of hamster embryo cells by betel tobacco extracts (1978) (11)
Bioimaging analysis of nuclear factor‐κB activity in Philadelphia chromosome‐positive acute lymphoblastic leukemia cells reveals its synergistic upregulation by tumor necrosis factor‐α‐stimulated changes to the microenvironment (2011) (11)
Screening of bioactive metabolites for pancreatic regeneration chemotherapy. (2004) (10)
Molecular design, chemical synthesis, and biological evaluation of agents that selectively photo-degrade the transcription factor estrogen receptor-α. (2011) (10)
Effects of AP-1 and NF-κB inhibitors on colonic endocrine cells in rats with TNBS-induced colitis (2016) (10)
Identification of a novel compound that inhibits osteoclastogenesis by suppressing nucleoside transporters (2016) (10)
Treatment with novel AP-1 and NF-κB inhibitors restores the colonic endocrine cells to normal levels in rats with DSS-induced colitis (2016) (10)
Targeting NF-kappaB and induction of apoptosis by novel NF-kappaB inhibitor dehydroxymethylepoxyquinomicin (DHMEQ) in Burkitt lymphoma cells. (2007) (10)
Induction of Apoptosis in Human Pancreatic Carcinoma Cells by a Synthetic Bleomycin‐like Ligand (1998) (10)
Synthesis and biological activities of hapalosin derivatives with modification at the C12 position. (2000) (10)
Anti-inflammatory effects of novel AP-1 and NF-κB inhibitors in dextran-sulfate-sodium-induced colitis in rats (2016) (10)
Inhibition of NF-kappa B activation by 9-methylstreptimidone isolated from Streptomyces (2006) (10)
Inostamycin, an Inhibitor of P‐Glycoprotein Function, Interacts Specifically with Phosphatidylethanolamine (1995) (9)
Inhibition of epidermal growth factor-induced activation of phospholipase C by psi-tectorigenin. (1991) (9)
Immunosuppressive Effects of DTCM-G, a Novel Inhibitor of the mTOR Downstream Signaling Pathway (2013) (9)
Inhibition of active HIV-1 replication by NF-kappaB inhibitor DHMEQ. (2010) (9)
Enteroendocrine cells, stem cells and differentiation progenitors in rats with TNBS-induced colitis (2016) (9)
Inhibition of IGF-1-Mediated Cellular Migration and Invasion by Migracin A in Ovarian Clear Cell Carcinoma Cells (2015) (9)
Combined inhibition of NF-κB and Bcl-2 triggers synergistic reduction of viability and induces apoptosis in melanoma cells. (2014) (9)
Enhancement of sensitivity by bestatin of acute promyelocytic leukemia NB4 cells to all-trans retinoic acid. (2002) (9)
Dehydroxymethylepoxyquinomicin suppresses atopic dermatitis-like lesions in a stratum corneum-removed murine model through NF-κB inhibition (2019) (9)
Preparation of conophylline affinity nano-beads and identification of a target protein. (2009) (9)
Total synthesis of dephostatin, a novel protein tyrosine phosphatase inhibitor (1994) (9)
Designed ATRA analogue active against ATRA-resistant acute promyelocytic leukemia cells having a single nucleotide substitution in their retinoic acid receptor. (2007) (9)
Inhibition of tyrosine kinase and src oncogene functions by stable erbstatin analogues. (1992) (9)
Isolation and Characterization of New Anti-Inflammatory and Antioxidant Components from Deep Marine-Derived Fungus Myrothecium sp. Bzo-l062 (2020) (9)
Tyrosine kinase inhibitors inhibit multiple steps of the cell cycle of vascular smooth muscle cells. (1994) (9)
INHIBITION OF NF-KAPPA B ACTIVATION BY PENICILLIC ACID AND DIHYDROPENICILLIC ACID ISOLATED FROM FUNGI (2008) (9)
Induction of histidine decarboxylase in macrophages inhibited by the novel NF-kappaB inhibitor (-)-DHMEQ. (2009) (9)
Immunomodulatory Effect of Nuclear Factor-&kgr;B Inhibition by Dehydroxymethylepoxyquinomicin in Combination With Donor-Specific Blood Transfusion (2012) (8)
Induction of apoptosis by erbstatin in mouse leukemia L1210 cells (1994) (8)
Peritoneal NF-κB as a Possible Molecular Target for Suppression of Various Cancers and Inflammation (2013) (8)
Rational design, synthesis and in vitro evaluation of novel exo-methylene butyrolactone salicyloylamide as NF-κB inhibitor. (2017) (8)
p53 dysfunction precedes the activation of nuclear factor-κB during disease progression in mice expressing Tax, a human T-cell leukemia virus type 1 oncoprotein. (2013) (8)
Anti‑inflammatory effects of the NF‑κB inhibitor dehydroxymethylepoxyquinomicin on ARPE‑19 cells. (2020) (8)
HIGH GRADE GLIOMAS (2012) (8)
Inhibition of NF-kappaB with Dehydroxymethylepoxyquinomicin modifies the function of human peritoneal mesothelial cells. (2016) (8)
Inhibition of receptor activator of nuclear factor-κB ligand- or lipopolysaccharide-induced osteoclast formation by conophylline through downregulation of CREB. (2014) (8)
Induction of oncogene addiction shift to NF-kappaB by camptothecin in solid tumor cells. (2009) (8)
Synthesis and biological evaluation of molecular probes based on the 9-methylstreptimidone derivative DTCM-glutarimide. (2012) (8)
Dehydroxymethylepoxyquinomicin, a novel nuclear factor‐κB inhibitor, prevents inflammatory injury induced by interferon‐γ and histamine in NCTC 2544 keratinocytes (2010) (8)
Anti-Inflammatory Effect of Dehydroxymethylepoxyquinomicin, a Nuclear factor–κB Inhibitor, on Endotoxin-Induced Uveitis in Rats In vivo and In vitro (2020) (8)
Formal total synthesis of aglaiastatin: Pd(0)mediated construction of benzofurocyclopentane system (2000) (8)
Relation between in vivo effects and in vitro effects of serine and thiol proteinase inhibitors. (1983) (8)
Poly (ADP-ribose) polymerase inhibition synergizes with the NF-κB inhibitor DHMEQ to kill hepatocellular carcinoma cells. (2014) (8)
Growth Inhibitory Effects of Dipotassium Glycyrrhizinate in Glioblastoma Cell Lines by Targeting MicroRNAs Through the NF-κB Signaling Pathway (2019) (8)
Inhibition of RANKL- and LPS-induced osteoclast differentiations by novel NF-κB inhibitor DTCM-glutarimide. (2015) (8)
NF‑κB inhibitor DHMEQ inhibits titanium dioxide nanoparticle‑induced interleukin‑1β production: Inhibition of the PM2.5‑induced inflammation model. (2018) (8)
Low-Molecular-Weight Protease Inhibitors of Microbial Origin (1993) (8)
Inhibition of the NF-κB pathway as a candidate therapeutic strategy for cryopyrin-associated periodic syndrome (2014) (8)
Synthesis of the Indole Core Structures of Conophylline (2008) (8)
Apoptosis in Mouse Amniotic Epithelium Is Induced by Activated Macrophages Through the TNF Receptor Type 1/TNF Pathway1 (2011) (7)
Synthesis and structure-activity relationship of ribofuranosyl echiguanine analogs as inhibitors of phosphatidylinositol 4-kinase (1998) (7)
Anoikis induction and inhibition of peritoneal metastasis of pancreatic cancer cells by a nuclear factor-κB inhibitor, (-)-DHMEQ. (2013) (7)
Modification of Cellular Membrane Functions by Pendolmycin (1989) (7)
The plant alkaloid conophylline inhibits matrix formation of fibroblasts (2018) (7)
Abnormal differentiation of stem cells into enteroendocrine cells in rats with DSS-induced colitis (2017) (7)
Antineoplastic Effects of NF-κB Inhibition by DHMEQ (Dehydroxymethylepoxyquinomicin) Alone and in Co-treatment with Radio-and Chemotherapy in Medulloblastoma Cell Lines. (2018) (7)
IkappaBalpha independent induction of NF-kappaB and its inhibition by DHMEQ in Hodgkin/Reed-Sternberg cells. (2007) (7)
A novel cyclic lipoundecapeptide, pholipeptin, isolated from Pseudomonas sp. (1995) (7)
A chemo-enzymatic expeditious route to racemic dihexanoyl (2R*,3R*,4R*)-dehydroxymethylepoxyquinomycin (DHMEQ), the precursor for lipase-catalyzed synthesis of the potent nuclear factor-κB inhibitor, (2S,3S,4S)-DHMEQ. (2012) (7)
Interferon gamma induces steroid sulfatase expression in human keratinocytes. (2012) (7)
Conophylline Inhibits Hepatocellular Carcinoma by Inhibiting Activated Cancer-associated Fibroblasts Through Suppression of G Protein–coupled Receptor 68 (2021) (7)
Down-regulation of TNF-α receptors by conophylline in human T-cell leukemia cells (2003) (7)
Mutagenicity of anthracycline glycosides and bleomycins in Salmonella assay system. (1987) (7)
Anticancer Activity of Novel NF-κB Inhibitor DHMEQ by Intraperitoneal Administration (2020) (7)
Dehydroxymethylepoxyquinomicin (DHMEQ) can suppress tumour necrosis factor‐α production in lipopolysaccharide‐injected mice, resulting in rescuing mice from death in vivo (2011) (7)
Pholipeptin, a Novel Cyclic Lipoundecapeptide from Pseudomonas fluorescens. (1997) (7)
A new NF-κB inhibitor based on the amino-epoxyquinol core of DHMEQ. (2010) (7)
Selective growth inhibition by sangivamycin of human umbilical vein endothelial cells. (2001) (7)
Enzyme-catalyzed resolution of 3,8-dioxatricyclo[3.2.1.02,4]octane-6-carboxylic esters and the application to the synthesis of 3-epishikimic acid (2009) (7)
Biological activities of alpha-mangostin derivatives against acidic sphingomyelinase. (2003) (7)
Enhancement of CDP-DG:inositol transferase activity in src- and erbB2-transformed cells. (1994) (7)
Induction of erythroid differentiation in leukaemic K562 cells by an S-adenosylhomocysteine hydrolase inhibitor, aristeromycin. (1995) (7)
Inhibition of cellular adhesion in human umbilical vein endothelial cells by NF-kappaB inhibitor DHMEQ under flow. (2005) (6)
Activation of apoptosis by caspase-3-dependent specific RelB cleavage in anticancer agent-treated cancer cells: involvement of positive feedback mechanism. (2015) (6)
Inhibition of NO-induced β-cell death by novel NF-κB inhibitor (-)-DHMEQ via activation of Nrf2-ARE pathway. (2013) (6)
Suppression by herbimycin A of 12-O-tetradecanoylphorbol-13-acetate-induced dissociation of cells and morphological changes in cultured FL and MDCK cells. (1987) (6)
Structure-activity relationship of 9-methylstreptimidone, a compound that induces apoptosis selectively in adult T-cell leukemia cells. (2012) (6)
NF-κB and STAT3 co-operation enhances high glucose induced aggressiveness of cholangiocarcinoma cells. (2020) (6)
Anti-tumor activity of dehydroxymethylepoxyquinomicin against human oral squamous cell carcinoma cell lines in vitro and in vivo. (2011) (6)
Conophylline and betacellulin-delta4: an effective combination of differentiation factors for pancreatic beta cells. (2007) (6)
Novel p-terphenyl glycoside with a rare 2,6-dideoxyhexopyranose moiety from Actinomycete strain SF2911 that inhibits cancer cell migration (2017) (6)
Dehydroxymethylepoxyquinomicin Inhibits Expression and Production of Inflammatory Mediators in Interleukin-1β-induced Human Chondrocytes (2010) (6)
Synthesis of C-oxetanosyl-thiazole and its carbocyclic analog nucleosides as potential chemotherapeutic agents (1996) (6)
Dehydroxymethylepoxyquinomicin, a novel nuclear factor–κB inhibitor, reduces chemokines and adhesion molecule expression induced by IL-1β in human corneal fibroblasts (2015) (6)
Inhibition of chemically induced sister chromatid exchanges by protease inhibitors from Streptomyces. (1980) (6)
Role of NF-kB in Thyroid Cancer (2011) (6)
Involvement of tyrosine kinase in growth factor-induced phospholipase C activation in NIH3T3 cells. (1993) (6)
Comparison of anti-atopic dermatitis activities between DHMEQ and tacrolimus ointments in mouse model without stratum corneum. (2019) (5)
A simple and reliable method for determining plasma concentration of dehydroxymethylepoxyquinomicin by high performance liquid chromatography with mass spectrometry. (2008) (5)
Inhibition of NF-Kappa B Activation by 9-Methylstreptimidone Isolated from Streptomyces. (2007) (5)
Synthesis and structure-activity relationship of dehydroxymethylepoxyquinomicin analogues as inhibitors of NF-kappaB functions. (2002) (5)
Inhibition of G protein-mediated differentiation of PC12 cells by an IMP dehydrogenase inhibitor, oxanosine (1994) (5)
Tyrosine kinase inhibitor, methyl 2,5-dihydromethylcinnimate, induces PML nuclear body formation and apoptosis in tumor cells. (2007) (5)
Effects of DHMEQ, a novel nuclear factor-kappab inhibitor, on beta cell dysfunction in INS-1 cells. (2008) (5)
A nuclear factor-κB inhibitor, dehydroxymethylepoxyquinomicin, ameliorates GVHD in allogeneic bone marrow transplantation. (2015) (5)
DHMEQ, a novel NF-κB inhibitor, enhances anti-tumor activity of taxanes in anaplastic thyroid cancer cells (2008) (5)
Involvement of conserved tryptophan residues for secretion of TIMP-2 (2013) (5)
Inhibition of experimental metastasis by enzyme inhibitors from microorganisms and plants. (1996) (5)
THE EFFECT OF A NOVEL NUCLEAR FACTOR KAPPAB ACTIVATION INHIBITOR ON RENAL INFLAMMATORY RESPONSES IN RATS WITH RENAL ISCHEMIA REPERFUSION INJURY: 1630 (2010) (4)
Inhibition of Cellular and Animal Inflammatory Disease Models by NF-κB Inhibitor DHMEQ (2021) (4)
Administration of conophylline and betacellulin-delta4 increases the beta-cell mass in neonatal streptozotocin-treated rats. (2009) (4)
Dissociated release of tetrahydrobiopterin and nitric oxide by lipopolysaccharide from mouse neuroblastoma cells (1996) (4)
Chloptosin, an Apoptosis‐Inducing Dimeric Cyclohexapeptide Produced by Streptomyces. (2000) (4)
Induction of morphological and enzymic differentiation in rat pheochromocytoma PC12h cells by stable erbstatin analogues. (1993) (4)
Difference in sensitivity of Salmonella typhimurium strains to alkylating agents (1978) (4)
Induction of flat morphology in K-ras-transformed fibroblasts by lycorine, an alkaloid isolated from the tropical plant Eucharis grandiflora. (1997) (4)
Inhibition of serum-induced M-phase progression by a tyrosine kinase inhibitor, erbstatin. (1993) (4)
Synthesis and determination of the relative structure of akaterpin, a potent inhibitor of PI-PLC (2011) (4)
Biosynthetic preparation of radioactively labeled erbstatin. (1992) (4)
Induction of anchorage independent growth of normal fibroblasts by growth factors. (1982) (4)
Synergistic effect of 5-azacytidine and NF-κB inhibitor DHMEQ on apoptosis induction in myeloid leukemia cells. (2013) (4)
Brefeldin A exerts differential effects on anaplastic lymphoma kinase positive anaplastic large cell lymphoma and classical Hodgkin lymphoma cell lines (2015) (4)
Synthesis of echiguanine analogs and their ribofuranosyl glycosides that inhibit phosphatidylinositol 4-kinase. (1997) (4)
Inhibition of human immunodeficiency virus-associated reverse transcriptase by 14-O-acyladriamycins. (1989) (4)
Differential behavior of VEGF receptor expression and response to TNP-470 in two immortalized human endothelial cell lines. (2000) (4)
Syntheses of oxanosine and carbocyclic oxanosine derivatives as anti-HIV agents. (2000) (4)
Herbimycin A Suppresses the Reduction of Gap‐junctional Intercellular Communication Induced by Tumor‐promoting Phorbol Ester in 3T3‐L1 Cells (1989) (3)
[Protein-tyrosine phosphatase inhibitors]. (2000) (3)
Activation of Akt involves resistance to NF-κB inhibition and abrogation of both triggers synergistic apoptosis in lung adenocarcinoma cells. (2014) (3)
Small cell lung cancer and other thoracic malignancies (2012) (3)
Hypoxia-Adapted CML Cells Are More Primitive Population and Are Eradicated by Glyoxalase-1 Inhibitors. (2009) (3)
A New Bioactive Steroidal Saponin, Furcreastatin, from the Plant Furcraea foetida (2000) (3)
Biosynthesis of the lipophilic side chain in the cyclic hexadepsipeptide antibiotic IC101. (2002) (3)
Down-regulation of TNF-alpha receptors by conophylline in human T-cell leukemia cells. (2003) (3)
NF-кB inhibition by DHMEQ: in vitro antiproliferative effects on pilocytic astrocytoma and concise review of the current literature (2020) (3)
Extractives of the Genus Carpinus I. Diarylheptanoids of sawashiba Carpinus cordata Blume wood(1) (1988) (3)
Lipase-catalyzed enantio- and regioselective transformation of 3-epi-shikimic acid derivatives as the key step for the entry of polyoxygenated carbacycles (2010) (3)
Cellular Signal Transductions and Their Inhibitors Derived from Deep-Sea Organisms (2021) (3)
Target‐selective degradation of cancer‐related proteins by novel photosensitizers for molecular‐targeted photodynamic therapy (2009) (3)
Synthesis of ribofuranosyl glycosides of echiguanines A and B, inhibitors of phosphatidylinositol 4-kinase (1996) (3)
pH-dependent inhibition of mushroom tyrosinase by N-substituted N-nitrosohydroxylamines. (2008) (3)
Design and synthesis of biotinylated DHMEQ for direct identification of its target NF-κB components. (2011) (3)
Isolation of ketomycin from Actinomycetes as an inhibitor of 2D and 3D cancer cell invasion (2018) (3)
pH-dependent inhibition of mushroom tyrosinase by N-substituted N-nitrosohydroxylamines (2008) (3)
Antitumor Effect of Piericidin B1 N‐Oxide. (1994) (3)
Novel anti-inflammatory agent 3-[(dodecylthiocarbonyl)-methyl]-glutarimide ameliorates murine models of inflammatory bowel disease (2016) (3)
Screening of new bioactive metabolites for diabetes therapy (2013) (3)
Synthesis and inhibitory activity against phosphatidylinositol 4-kinase of echiguanine analogs. (1999) (3)
INHIBITION OF NF-κB AND CELLULAR INVASION BY NOVEL FLAVONOID DISMAL IN OVARIAN CARCINOMA CELLS (2016) (3)
Corrigendum to "poly (ADP-ribose) polymerase inhibition synergizes with the NF-κB inhibitor DHMEQ to kill hepatocellular carcinoma cells" [Biochim. Biophys. Acta 1853(12)(2015) 3224-3234]. (2014) (3)
Enantiospecific Total Synthesis of a β-Glucosidase Inhibitor, Cyclophellitol. (1990) (2)
DEPHOSTATIN, A NOVEL PROTEIN TYROSINE PHOSPHATASE (2006) (2)
DTCM-glutarimide Delays Growth and Radiosensitizes Glioblastoma. (2019) (2)
Intravenous Administration of Dehydroxymethylepoxyquinomicin With Polymer Enhances the Inhibition of Pancreatic Carcinoma Growth in Mice (2021) (2)
Identification of poly(rC) binding protein 2 (PCBP2) as a target protein of immunosuppressive agent 15-deoxyspergualin. (2016) (2)
Biosynthetic Study and Radioisotope Labeling of Inostamycin (1994) (2)
NF-κB INHIBITOR (2006) (2)
Screening of oncogene function inhibitors from microbial secondary metabolites (1995) (2)
Herbimycin A induces G1 arrest through accumulation of p27(Kip1) in cyclin D1-overexpressing fibroblasts. (2000) (2)
Induction of transient differentiation of rat pheochromocytoma PC12 cells by tyrosine kinase inhibitors (1992) (2)
A New 1,2-Naphthoquinone Derivative with Anti-lung Cancer Activity. (2022) (2)
Inhibition of Lysenin-induced Hemolysis by All-E-Lutein Derived from the Plant Dalbergia latifolia (2012) (2)
Design and synthesis of 15-deoxyspergualin–biotin conjugates as novel binding probes for target protein screening (2016) (2)
Synthesis and biological activity of 5-[(2,5-dihydroxybenzyl)amino]salicylic acid analogs as inhibitors of EGF receptor-associated protein tyrosine kinase (1997) (2)
The differentiation-promoting potential of a cytostatic fluoro-pyranosyl adriamycin analog (FAD 104). (1989) (2)
Growth stimulation of hamster embryonic fibroblasts by phorbol esters. (1980) (2)
Cytostatic in vitro effects of DTCM-glutarimide on bladder carcinoma cells. (2012) (2)
A Selective NF-?B Inhibitor, DHMEQ, Inhibits Allergic Inflammation And Airway Remodeling In A Murine Model Of Asthma (2011) (2)
FIRST SYNTHESIS OF ENANTIOMERICALLY PURE CARBOCYCLIC OXANOSINE AS A POTENTIAL CHEMOTHERAPEUTIC AGENT (1996) (2)
Inhibition of T Cell Receptor-mediated Signal Transduction by Erbstatin (1994) (2)
Dehydroxymethylepoxyquinomicin, a novel nuclear factor-κB inhibitor, prevents the development of cyclosporine A nephrotoxicity in a rat model (2020) (2)
[Biological activity of oncogene function inhibitors isolated from microorganisms]. (1992) (1)
Phosphatidylinositol 4-kinase assay in ovarian carcinoma cells. (2001) (1)
Diabetes mellitus: rational basis, clinical approach and future therapy. (2004) (1)
Synthesis of Epoxyquinols via Anodic Oxidation and Evaluation of NF-κB Inhibitory Activity (2010) (1)
Activator protein-1 inhibition by 3-[(dodecylthiocarbonyl)methyl]-glutamaride impairs invasion and radiosensitizes osteosarcoma cells in vitro. (2013) (1)
The designed NF-κB inhibitor, DHMEQ, inhibits KISS1R-mediated invasion and increases drug-sensitivity in mouse plasmacytoma SP2/0 cells (2021) (1)
Proceedings of The 28th Annual Meeting of the Japan Human Cell Society 23 August 2009 Tsukuba, Ibaraki, Japan (2010) (1)
761: Enhanced Chemosensitivity to CPT-11 by a Novel NF-KB Inhibitor, DHMEQ in Bladder Cancer (2007) (1)
3-[(Dodecylthiocarbonyl)Methyl]-Glutarimide Attenuates Graft Arterial Disease by Suppressing Alloimmune Responses and Vascular Smooth Muscle Cell Proliferation (2015) (1)
Biological Activities of α-Mangostin Derivatives Against Acidic Sphingomyelinase. (2004) (1)
Microenvironmental Up-Regulation of NF-kB Activity Via P65-Dependent and Independent Pathways in a Bioimaging Model of Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia. (2007) (1)
Medical ethics in Japan. (1988) (1)
A NOVEL IMMUNOSUPPRESSIVE AGENT, DTCM-GLUTARIMIDE MARKEDLY PROLONGS CARDIAC ALLOGRAFT SURVIVAL IN MOUSE WHEN COMBINED WITH DONOR SPECIFIC TRANSFUSION: 478 (2010) (1)
Determination of the absolute structure of (+)-akaterpin. (2012) (1)
[Screening of phosphatidylinositol turnover inhibitors and regulation of cell cycle progression]. (1997) (1)
Man-designed bleomycins. Iron complexation and nucleotide sequence cleavage by synthetic models of bleomycin (1988) (1)
Formal Total Synthesis of Aglaiastatin: Pd(0)-Mediated Construction of Benzofurocyclopentane System. (2000) (1)
DHMEQ enhances the cytotoxic effect of cisplatin and carboplatin in ovarian cancer cell lines. (2021) (1)
Causes and mechanisms of peritoneal fibrosis and possible application of NF-κB inhibitor for prevention and treatment (2019) (1)
[Molecular design of apoptosis inducing agents derived from bleomycin]. (1997) (1)
A Selective NFkB Inhibitor, DHMEQ, Reduced Atherosclerosis in ApoE-deficient mice (2006) (1)
Inhibition of human immunodeficiency virus-associated reverse transcriptase by aminoacridines. (1988) (1)
This information is current as TRAIL-Enhanced Apoptosis in Cancer Cells Inhibitor NPI-0052 Contributes to its Expression by the Novel Proteasome Repressor Activity of DR5 Transcription and Inhibition of Yin Yang 1-Dependent (2013) (1)
Synthesis and Stereochemistry of Valinoctin A, a Novel Farnesyltransferase Inhibitor from Streptomyces sp. (1995) (1)
Synthesis and anti-HIV activity of unusual nucleoside oxanosine derivatives. (1999) (1)
EFFECT OF INHIBITION OF TISSUE FACTOR ON NONHUMAN PRIMATE ISLET ALLOGRAFT SURVIVAL (2006) (1)
Down-regulation of NF kappa B activation is an effective therapeutic modality in acquired platinum-resistant bladder cancer (2015) (1)
Preparation of radioactively labeled dehydroxymethyl-epoxyquinomicin, an NF-kappa B function inhibitor. (2003) (1)
Microbial Secondary Metabolites Inhibiting Oncogene Functions (1991) (1)
A Novel Metal‐Chelating Inhibitor of Protein Farnesyltransferase. (2003) (1)
Screening of bioactive metabolites that inhibit cancer growth and natural immune reactions (2008) (1)
[Screening of bioactive metabolites that suppress inflammation]. (2007) (1)
A Selective NF-kB Inhibitor, DHMEQ, Inhibits Allergic Inflammation in a Murine Model of Asthma. (2009) (1)
Chemo-Immunosensitization of Resistant B-NHL as a Result of Rituximab (anti-CD20 mAb)-Mediated Inhibition of Cell Survival Signaling Pathways (2008) (1)
Identification of bleomycin-treated DNA fragments by molecular cloning. (1985) (1)
Inhibition of mutagenesis in Chinese hamster V-79 cells by antioxidants. (1980) (1)
Cellular Anti-Inflammatory and Antioxidant Activities of Bamboo Sasa albomarginata Leaf Extract and Its Constituent Coumaric Acid Methyl Ester (2022) (1)
Oncogene function inhibitors of microbial origin. (1994) (1)
DHMEQ, a New NF-kappa B Inhibitor, Suppresses Innate and Subsequent Allo-Immune Responses, and Permits a Long-Term Allogeneic Islet Engraftment Together with Tacrolimus (2010) (0)
A NOVEL PROTEIN TYROSINE PHOSPHATASE INHIBITOR PRODUCEDBY Streptomyces II . STRUCTURE DETERMINATION (2006) (0)
The First Direct Synthesis of α‐Mangostin, a Potent Inhibitor of the Acidic Sphingomyelinase. (2002) (0)
A NOVEL NF-KB INHIBITOR, DEHYDROXYMETHYLEPOXYQUINOMICIN, SUPPRESSES THE IMMUNOSTIMULATORY FUNCTION OF HUMAN DENDRITIC CELLS: 1930 (2008) (0)
DHMEQ effect of ICAM-1, VCAM-1 and rantes expression in nasal polyps (2009) (0)
Importance of Novel Intraperitoneal Therapy of NF-kappa B Inhibitor DHMEQ (2019) (0)
Dehydroxymethylepoxyquinomicin (DHMEQ) Inhibits TNF-Alpha Induced Expression of ICAM-1, IL-8 and MCP-1 in Human Retinal Pigment Epithelial Cells in vitro (2009) (0)
Screening of microbial secondary metabolites that inhibit endothelial cell growth (2008) (0)
Abstract 3840: Evaluation of the synergetic effect of a combination of dehydroxymethylepoxyquinomicin and gemcitabine on liver metastasis of pancreatic cancer (2012) (0)
Combined effect of dehydroxymethylepoxyquinomicin and gemcitabine in a mouse model of liver metastasis of pancreatic cancer (2012) (0)
Potential of NF-κB Inhibition in the Treatment of Chronic Lymphocytic Leukemia (2014) (0)
Effect of glucose on the mutagenic sensitivity of Salmonella typhimurium tester strains (1978) (0)
INHIBITION OF NF-KAPPA B AND/OR NFAT ACTIVATION AUGMENTS OR ABROGATES IMMUNOMODULATORY EFFECTS OF DONOR SPECIFIC TRANSFUSION.: 50 (2008) (0)
Therapeutic impact of NFκB inhibitor against human bladder cancer in murine xenograft model (2005) (0)
Total Synthesis of Dephostatin, a Novel Protein Tyrosine Phosphatase Inhibitor. (1994) (0)
[Inhibitors of oncogene product functions]. (1990) (0)
HIGH GRADE GLIOMAS AND DIPG (2014) (0)
VEGF DRIVEN INTERPLAY OF INFLAMMATION AND PRIMITIVE CAPILLARY ANGIOGENESIS IN CHRONICALLY REJECTING (2006) (0)
Human Cancer Biology Impairment of Plasmacytoid Dendritic Cells for IFN Production by the Ligand for Immunoglobulin-Like Transcript 7 Expressed on Human Cancer Cells (2009) (0)
Synergistic effect of 17-allylamino-17-demethoxygeldanamycin with dehydroxymethylepoxyquinomicin on the human anaplastic thyroid carcinoma cell line KTC2 (2021) (0)
Targeting NF-κB and Induction of Apoptosis by Dehydroxymethylepoxyquinomicin (DHMEQ) in Multiple Myeloma Cells. (2004) (0)
Tumor Necrosis Factor-α Contributes to Microenvironmental up- Regulation of NF-κB Activity in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: Implication for a Novel Therapeutic Target. (2008) (0)
M1759 A Novel Anti-Inflammatory Agent, Dtcm-Glutarimide, Attenuates Experimental Colitis in Mice (2010) (0)
P-331 Inhibition of macrophage activation by a synthetic analogue of epoxyquinomicin (2006) (0)
New NF-^|^kappa;B Inhibitor DHMEQ : Its Bio-organic Chemistry and Application to Anti-inflammatory and Anticancer Agent (2011) (0)
COMMENTARY. Biochemistry and Gene regulation of YY1 (2010) (0)
P-1 Isolation of Cyclic Lipopeptides Heptadepsin and Surfactin from Microorganisms as Inhibitors of Lipopolysaccharide Activity (2006) (0)
Abstract 4058: Possibility of clinical application of dehydroxymethylepoxyquinomicin in liver metastasis of pancreatic cancer (2010) (0)
Isolation of a Novel Cyclic Hexadepsipeptide Pipalamycin from Streptomyces as an Apoptosis-Inducing Agent (2002) (0)
Inhibition of macrophage activation and tumor growth in animals by DHMEQ, an NF-kappaB inhibitor (2005) (0)
P2.01-031 CCL Chemokines May Play an Important Role in Cisplatin Resistance (2017) (0)
Suppression of NF‐κB by dehydroxymethylepoxyquinomicin through reactive oxygen species and unfolded protein response (980.1) (2014) (0)
Therapeutic activity of plant-derived alkaloid conophylline on metabolic syndrome and neurodegenerative disease models (2017) (0)
ANTITUMOR EFFECT OF PIERICIDIN Bx TV-OXIDE (2006) (0)
Abstract A191: DHMEQ: A novel NF-kappaB inhibitor with good results in pediatric medulloblastoma cell lines. (2013) (0)
CCL chemokines may play an important role in cisplatin resistance: Topic: proteins in lung cancer and proteomics (Conference Abstract) (2017) (0)
MP-12.10 (2005) (0)
Synergistic anti-viral effect of oxanosine and ddI against human immunodeficiency virus. (2005) (0)
6635 A novel NF-kB inhibitor DHMEQ could suppress peritoneal dissemination of gastric cancer by anti-tumor/-adhesive effects in mice (2009) (0)
Inhibition of NF-κB Activation Augments the Effect of 5-Azacytidine On Acute Myeloid Leukemia Cell Line (2012) (0)
Synergy in Apoptosis Is Achieved in B-NHL by the Combination of Rituximab and the Novel Proteasome Inhibitor NPI-0052: Pivotal Role of Induction of the Immune Surveillance Cancer Gene Product RKIP (2008) (0)
DTCM-Glutarimide Hinders Growth of Childhood Leukemia Cells but Fails to Improve the Efficacy of Commonly Used Chemotherapeutic Agents (2016) (0)
Synthetic Study on Protein Tyrosine Phosphatase Inhibitor, Dephostatin, and Its Stable Analogues (2000) (0)
Design and Synthesis of Biotinylated DHMEQ for Direct Identification of Its Target NF-ϰB Components. (2012) (0)
THE EFFECT OF A NOVEL NUCLEAR FACTOR K (KAPPA) B ACTIVATION INHIBITOR ON THE RENAL INFLAMMATORY RESPONSES IN RENAL ISCHEMIA REPERFUSION IN RAT: 110 (2008) (0)
Targeting Inflammatory Mediators to Overcome Intrinsic and Acquired Cisplatin Resistance in Non-Small Cell Lung Cancer (2015) (0)
Generation of Active Oxygen in Bacterial Infections(The 4th Joint Symposium between Tokai University School of Medicine and Semmelweis University School of Medicine 7-9, June, 1993, Budapest) (1992) (0)
760: Association between Survivin Expression and Cell Proliferation in Renal Cell Carcinoma: Regulation of Survivin by Insulin-Like Growth Factor-1, Interferon-γ and a Novel NF-κB Inhibitor Dehydroxymethyl-Epoxyquinomicin (2004) (0)
Tu-P7:11 Hexyl-3,4-dephostatin-sensitive period in the early phase of insulin-induced adipocyte differentiation of 3T3-L1 cells (2006) (0)
AMPK-NF-κB axis modulates visual function during inflammation (2013) (0)
Synthesis of NF-ϰB Activation Inhibitors Derived from Epoxyquinomicin C. (2000) (0)
MP59-01 NOVEL NUCLEAR FACTOR-κB ACTIVATION INHIBITOR, DEHYDROXYMETHYLEPOXYQUINOMICIN, PREVENTS THE DEVELOPMENT OF CHRONIC CYCLOSPORINE NEPHROPATHY (2020) (0)
Nuclear Factor-Kappa B as a Molecular Target in Malignant Pleural Mesothelioma (2012) (0)
First Synthesis of Enantiomerically Pure Carbocyclic Oxanosine as a Potential Chemotherapeutic Agent. (1996) (0)
Basic and clinical interface in targeted cancer therapy (0)
Glyoxalase-I Inhibition Eliminates Hypoxia-Adapted CML Cells Resistant to Imatinib, Dasatinib, and INNO-406 (2008) (0)
556 Antineoplasic Effects of DHMEQ and Its Chemo- and Radio-sensitizing Potential in Pediatric Medulloblastoma Cells (2012) (0)
Synthesis of Sugar-Modified Derivatives of the Unusual Nucleoside Oxanosine and Its Carbocyclic Analogues as Potential Inhibitors of HIV. (2001) (0)
SUCCESSFUL ISLET TRANSPLANTATION FROM A SINGLE-DONOR BASED ON CD40-CD154 COSTIMULATION BLOCKADE PLUS NF-κB INHIBITION: 1048 (2010) (0)
Abstract 3674: Inhibition of noncanonical NF-kappa B activation by (−)-DHMEQ in vitro and in adult T-cell leukemia cells (2010) (0)
CP8-9 NF-_κB function inhibitor, DHMEQ as a treatment option for advanced urological cancer (2004) (0)
556 NOVEL NF-KAPPAB INHIBITOR DHMEQ: THE NEW STRATEGY FOR ACQUIRED CHEMO-RESISTANT BLADDER CANCER (2012) (0)
The alkylating agent MNNG is both a potent mutagen and a carcinogen. In the Salmonella test system, 0.02 mole of MNNG (2006) (0)
2P-0413 Two insulin-sensitizers differently affect insulin-induced adipogenesis (2003) (0)
M1656 Effect of a Novel NF-κB Inhibitor, DHMEQ, On Dextran Sulfate Sodium-Induced Colitis in Mice (2009) (0)
515 THE NOVEL NF-κB INHIBITOR DHMEQ SUPPRESSES THE GROWTH OF HUMAN HEPATIC CANCER CELLS THROUGH REDOX-DEPENDENT SIGNALING (2009) (0)
Role of RKIP in Sensitizing Tumor Cells to Photodynamic Therapy (2011) (0)
Abstract 137: Nuclear factor kappa B (NFκB) activation Impairs Vascular Endothelial Function in Type 2 Diabetic Mice (2012) (0)
Th eNove lNF- BInhibitor ,Dehydroxymethylepoxyquinomicin ,Prevents Loca lan dRemot eOrga nInjur yFollowin gIntestinal Ischemia/Reperfusio ni nRats (2008) (0)
6644 A novel NF-kB inhibitor DHMEQ suppressed peritoneal dissemination of pancreatic cancer in mouse xenograft model (2009) (0)
Anticancer Agents and Oncogene Function Inhibitors of Microbial Origin (1989) (0)
A Chemoenzymatic Expeditious Route to Racemic Dihexanoyl (2R*,3R*,4R*)‐Dehydroxymethylepoxyquinomycin (DHMEQ) (VII), the Precursor for Lipase‐Catalyzed Synthesis of the Potent Nuclear Factor‐ϰB Inhibitor, (2S,3S,4S)‐DHMEQ. (2013) (0)
EFFECT OF NF-FÉB INHIBITON BY DHMEQ ON ISLET TRANPLANTATION IN MICE: 763 (2008) (0)
276: Enhancement of Radiosensitivity by the Novel NF-κB Inhibitor DHMEQ in Prostate Cancer (2006) (0)
Conophylline inhibits pancreatic cancer progression via suppression of cancer promoting cytokines produced by cancer-associated fibroblast (2018) (0)
DTCM-GLUTARIMIDE, A NEW ACTIVATOR PROTEIN-1 (AP-1) INHIBITOR AMELIORATES TRANSPLANT VASCULOPATHY IN MICE: 1242 (2010) (0)
Induction of apoptotic cell death by tyrosine kinase inhibitor (1997) (0)
Inhibition of EGF-induced cytoskeletal change in A431 cells by inhibitors of phosphatidylinositol turnover. (1992) (0)
Screening of naturally occurring NF-kappa B inhibitors and application to mechanistic studies (2004) (0)
4: DHMEQ a novel therapeutic option for the treatment of inflammatory mediated cisplatin resistant non-small cell lung cancer (2015) (0)
4 DHMEQ, an NFkB inhibitor, inhibits cell proliferation and induces apoptosis in cisplatin resistant NSCLC (2013) (0)
Glyoxalase-I Is a Potential Therapeutic Target for Chronic Myelogenous Leukemia Cells That Have Acquired Drug Resistance through Adaptation to Hypoxia. (2007) (0)
Chemosensitization of CDDP-Resistant Multiple Myeloma Cell Lines Following Treatment with Anti-TfR IgG3-Av. (2005) (0)
Isolation of ketomycin from Actinomycetes as an inhibitor of 2D and 3D cancer cell invasion (2018) (0)
Dehydroxymethylepoxyquinomicin, a novel nuclear factor-κB inhibitor, prevents the development of cyclosporine A nephrotoxicity in a rat model (2020) (0)
[Modulators of oncogene product functions]. (1993) (0)
Direct and Indirect Anticancer Activity of Plant-Derived Alkaloid Conophylline. (2021) (0)
and Unfolded Protein Response B Suppression via Reactive Oxygen Species k Dehydroxymethylepoxyquinomicin for NF-Pleiotropic Potential of (2013) (0)
Cellular uptake and efflux and cytostatic activity of 4'-O-tetrahydropyranyladriamycin in adriamycin-sensitive and resistant tumor cell lines.:IN ADRIAMYCIN-SENSITIVE AND RESISTANT TUMOR CELL LINES (1984) (0)
507 Regulation of Hyaluronidase1 Enzymatic Activity by C-mannosylation (2012) (0)
A foretaste for pediatric glioblastoma therapy: targeting the NF-kB pathway with DHMEQ. (2023) (0)
Screening of immune function inhibitors with anticancer activity from microorganisms (2009) (0)
THE NOVEL NF-∼ ÈB INHIBITOR, DEHYDROXYMETHYLEPOXYQUINOMICIN (DHMEQ) PREVENTS LOCAL AND REMOTE ORGAN INJURY FOLLOWING INTESTINAL ISCHEMIA/REPERFUSION IN RATS: 1688 (2008) (0)
MP21-11 UP-REGULATED NFκB ACTIVATION IS A POTENT THERAPEUTIC TARGET IN ACQUIRED PLATINUM-RESISTANT BLADDER CANCER: THE EFFICACY OF NFκB BLOCKADE BY DEHYDROXYMETHYL DERIVATIVE OF EPOXYQUINOMICIN (DHMEQ) (2014) (0)
United States Patent ( 19 ) Umezawa et al . 54 1N-( 4-AMINO-3-FLUORO-2-HYDROX (2017) (0)
Management of malignancies by reduction of systemic immune reactions (2008) (0)
P5.05Isolation of novel cell migration inhibitor migracins from Streptomyces and inhibition of cellular invasion in ovarian carcinoma cells (2015) (0)
Publication of Kazuo Umezawa since 1990. Articles in Japanese are removed, so there are gaps in number. (2012) (0)
NFkB Transcription Factor as a Therapeutic Target in Uveal Melanoma (2008) (0)
Isolation, Synthesis, and Biological Activities of Signal Transduction Inhibitors (1996) (0)
89 Targeting nuclear factor-kappa B in malignant pleural mesothelioma (2013) (0)
Preface: Practical Molecular Targets for Suppression of Cancer (2013) (0)
Abstract 3968: Conophylline-target ARL6ip1 regulates Ran-mediated cellular migration and invasion in human colorectal cancer cells (2023) (0)
Enhanced antitumor activity of DHMEQ, a NF-κB Inhibitor, on Cholangiocarcinoma Cell Lines by Decreasing the Expression of ABC Transporters (2013) (0)
A NOVEL NF-KAPPA B INHIBITOR, DHMEQ, ATTENUATES ARTERIAL VASCULOPATHY.: 470 (2008) (0)
Inhibition of the Akt Pathway in MM Cell Lines by the Anti-TfR-IgG3-Avidin Fusion Protein (Anti-TfR-IgG3-Av): Role in Chemosensitization to CDDP-Induced Apoptosis (2008) (0)
Novel anti-inflammatory agent 3-[(dodecylthiocarbonyl)-methyl]-glutarimide ameliorates murine models of inflammatory bowel disease (2011) (0)
1052 DOES NF-KB ACTIVATION INHIBITOR, DHMEQ OVERCOME THE CHEMORESISTANCE TO CISPLATIN IN BLADDER CANCER? (2011) (0)
Interaction of Superoxide and Nitric Oxide in Reperfusion Injury(The 4th Joint Symposium between Tokai University School of Medicine and Semmelweis University School of Medicine 7-9, June, 1993, Budapest) (1992) (0)
Isolation of the Anti-Inflammatory Agent Myceliostatin from a Methionine-Enriched Culture of Myceliophthora thermophila ATCC 42464. (2023) (0)
977 Dehydroxymethylepoxyquinomicin, a Novel Inhibitor of NF-kB Efficiently Suppresses Invasion and Radiosensitizes Glioblastoma Cells (2012) (0)
THE EFFECTS OF DHMEQ, A NOBEL NF-KAPPA B INHIBITOR ON DEVELOPMENT OF OBLITERATIVE BRONCHIOLITIS IN HETEROTOPIC MURINE AIRWAY ALLO- TRANSPLANTATION: 1950 (2008) (0)
Inflammatory meditated mechanisms of cisplatin resistance in non‐small cell lung cancer: 68P (2016) (0)
Sensitization of prostate cancer cells to TRAIL-induced apoptosis by CDDP: Involvement of NF-κB, YY1 and RKIP in upregulation of DR5 expression (2005) (0)
Poster session 5: New drugs/targets: signaling pathways (2015) (0)
M1742 A Novel NF-κB Inhibitor, DHMEQ, Ameliorates Inflammatory Colonic Injuries in Mice (2010) (0)
Abstract 3223: Active enhancement of anti-tumor effect by NF-κB inhibitor DHMEQ using PMBN conjugated with anti-EGFR antibody in human pancreatic adenocarcinoma cells in vivo and in vitro (2011) (0)
INDUCTION OF IMMUNOSUPPRESSIVE DENDRITIC CELLS BY A NOVEL NUCLEAR FACTOR-KAPPA B INHIBITOR, DHMEQ: 817 (2008) (0)
Synthesis of C-Oxetanosylthiazole and Its Carbocyclic Analogue Nucleosides as Potential Chemotherapeutic Agents. (1996) (0)
Effect of DHMEQ, a NF-kappaB Inhibitor, on Nasal Cultures (2010) (0)
Abstract 4218: Potential roles of NF-kappa B pathways in breast cancer-initiating cells (2010) (0)
A NOVEL NF‐?B INHIBITOR DEHYDROXYMETHYLEPOXYQUINOMICIN PREVENTS ACUTE REJECTION OF KIDNEY ALLOGRAFTS IN A RAT MODEL: MP74‐15 (2017) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Kazuo Umezawa?

Kazuo Umezawa is affiliated with the following schools:

Kazuo Umezawa's Academic­Influence.com Rankings

Kazuo Umezawa's Degrees

Similar Degrees You Can Earn

Why Is Kazuo Umezawa Influential?

Kazuo Umezawa's Published Works

Published Works

What Schools Are Affiliated With Kazuo Umezawa?

Kazuo Umezawa's AcademicInfluence.com Rankings